EUVIMEDEUVIMED entdecken
Open Access

Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study

Hamidreza Jamaati iD, Saeed Karimi iD, Yunes Panahi, Shahnam Arshi, Maryam Hajimoradi iD, Fatemeh Sadat Hosseini-Baharanchi iD, Fariba Ghorbani iD, Seyed Mohsen Zahraei, Fatemeh Nouri iD, Ali Akbari Sari iD, Mahshad Goharimehr iD, Abdolreza Mohamadnia iD und 17 weitere

International Journal of Health Policy and Management · 2025

DOI: 10.34172/ijhpm.8852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Health Policy and Management, 2025. Verfasst von Hamidreza Jamaati und 28 weiteren Autor:innen. Beteiligte Einrichtung: Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Scie…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Mass Vaccination, Immunization Programs. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The global challenges posed by COVID-19 vaccinations require careful consideration by decision-makers at both the global and national levels, particularly in developing countries. This study aimed to evaluate the health and economic implications of implementing vaccination programs.

Methods

Two scenarios, one involving vaccination and the other without, were analyzed using the Markov Susceptible-Infectious-Recovered (SIR) model. For the vaccination scenario, real-world data, such as age-specific vaccination coverage, hospitalization rates, and mortality, were obtained from the Medical Care Monitoring Center (MCMC) and national COVID-19 registry during the Omicron wave in Iran. For the counterfactual non-vaccination scenario, we relied on model-based assumptions using published literature and expert input to estimate infection rates and clinical outcomes in the absence of vaccination. The Incremental CostEffectiveness Ratio (ICER) of the COVID-19 vaccination program was calculated by comparing the incremental cost per unit of Quality-Adjusted Life Year (QALY) generated to a willingnessto-pay threshold (WTP) equivalent to 1 time the Gross Domestic Product (GDP) per capita, approximately $4091 US. One-way sensitivity analysis was conducted to ensure the reliability of the results.

Results

Overall, 2098495 extra QALYs were generated by vaccination, incurring a total extra cost of $853.78 million. The vaccination program resulted in an average of 0.035 incremental QALYs at an additional cost of $14.08 per person. The average ICER for adult vaccination was $ 406.85 per QALY, indicating that it is a highly cost-effective strategy compared to nonvaccination across all age groups. Vaccinating elderly individuals proved to be the most costeffective approach among all age categories.

Conclusion

The integrated Markov-SIR model used in this study provides valuable insights into both the health and economic impact of the COVID-19 vaccination program in Iran. These findings support the implementation of vaccination strategies and provide a framework for decision-makers to consider when formulating policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesMass VaccinationImmunization ProgramsHumansIranCost-Benefit AnalysisCost-Effectiveness AnalysisQuality-Adjusted Life YearsMarkov ChainsAdultMiddle Aged

Stichwörter der Autor:innen

COVID-19 VaccinationCost-EffectivenessEconomic EvaluationICERIranQALY

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Science, Tehran, Iran.
  • Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Center for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Iran.
  • Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Hamidreza Jamaati, Saeed Karimi, Maryam Hajimoradi, Fatemeh Sadat Hosseini-Baharanchi, Fariba Ghorbani, Fatemeh Nouri, Ali Akbari Sari, Mahshad Goharimehr, Abdolreza Mohamadnia, Payam Tabarsi, Farzaneh Dastan, Babak Sharif-Kashani, Majid Marjani, Farin Rashid Farokhi, Seyed Mohammad Reza Hashemian, Mojtaba Nouhi, Katayoun Tayeri, Sima Noorali, Farnaz Ahmadi, Makan Sadr, Rajabali Daroudi, Shadi Shafaghi

Zitieren

APA

Jamaati, H., Karimi, S., Panahi, Y., Arshi, S., Hajimoradi, M., Hosseini-Baharanchi, F. S., Ghorbani, F., Zahraei, S. M., Nouri, F., Sari, A. A., Goharimehr, M., Mohamadnia, A., Tabarsi, P., Dastan, F., Sharif-Kashani, B., Marjani, M., Farokhi, F. R., Hashemian, S. M. R., Noorizadeh, M., …, & Shafaghi, S. (2025). Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study. International Journal of Health Policy and Management. https://doi.org/10.34172/ijhpm.8852

Vancouver

Jamaati H, Karimi S, Panahi Y, Arshi S, Hajimoradi M, Hosseini-Baharanchi FS, et al. Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study. International Journal of Health Policy and Management. 2025. doi:10.34172/ijhpm.8852

BibTeX
@article{Jamaati2025,
  author = {Jamaati, Hamidreza and Karimi, Saeed and Panahi, Yunes and Arshi, Shahnam and Hajimoradi, Maryam and Hosseini-Baharanchi, Fatemeh Sadat and Ghorbani, Fariba and Zahraei, Seyed Mohsen and Nouri, Fatemeh and Sari, Ali Akbari and Goharimehr, Mahshad and Mohamadnia, Abdolreza and Tabarsi, Payam and Dastan, Farzaneh and Sharif-Kashani, Babak and Marjani, Majid and Farokhi, Farin Rashid and Hashemian, Seyed Mohammad Reza and Noorizadeh, Mostafa and Nouhi, Mojtaba and Tayeri, Katayoun and Noorali, Sima and Ahmadi, Farnaz and Sadr, Makan and Moradkhani, Azadeh and Ahmadinia, Mahdi and Astani, Bahamin and Daroudi, Rajabali and Shafaghi, Shadi},
  title = {Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study},
  journal = {International Journal of Health Policy and Management},
  year = {2025},
  doi = {10.34172/ijhpm.8852}
}
Kostenlos starten →